Chromosomal microarray (CMA) is currently the first-tier genetic test for detection copy number variations (CNVs) in patients with unexplained intellectual disabilities/developmental delay (ID/DD), autism spectrum disorders (ASD), and multiple congenital anomalies (MCA). Its improved diagnostic yield over standard chromosome analysis and other methods for the identification of the underlying causes of complex diseases.